I disagree. I think it's just market sentiment and impatience. The fact is that even if the FDA comes back and tells IXC that they need to do 2 trials, it's not catastrophic. They still have an outstanding drug, excellent data, and plenty of cash in the bank. They're still a very suitable takeover target. This is the end game
IXC Price at posting:
90.5¢ Sentiment: Hold Disclosure: Held
